Mayo Clinic, Rochester, MN, USA.
Northwell Health, New Hyde Park, NY, USA; Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Respir Med. 2024 Jul;228:107660. doi: 10.1016/j.rmed.2024.107660. Epub 2024 May 9.
This study aimed to evaluate the association between the number of non-cystic fibrosis bronchiectasis (bronchiectasis) exacerbations during baseline and follow-up (objective 1) and to identify longitudinal changes in FEV associated with exacerbation frequency (objective 2).
This was a retrospective cohort study of adult patients enrolled in the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry September 2008 to March 2020. Objective 1 outcome was association between exacerbations during baseline (24 months) and 0-to-24 month and 24-to-48 month follow-up windows. Objective 2 outcomes were change in FEV and FEV % predicted over 24 months stratified by baseline exacerbation frequency.
Objective 1 cohort (N = 520) baseline frequency of any exacerbations was 59.2%. Overall, 71.4% and 75.0% of patients with ≥1 baseline exacerbations had ≥1 exacerbations during the 0-to-24 and 24-to-48 month follow-ups. Having ≥1 exacerbation during baseline was significantly associated with ≥1 exacerbation during the 0-to-24 month (P = 0.0085) and 24-to-48 month follow-ups (P=<0.0001). Objective 2 cohort (N = 431) baseline FEV was significantly lower in patients who had more exacerbations; however, decline in FEV from baseline was not significantly different between patients with 0, 1, and ≥2 exacerbations. In patients with more baseline exacerbations, FEV % predicted was significantly lower at baseline (P < 0.0001) and at 12 (P = 0.0002) and 24 month follow-ups (P < 0.0001).
Patients with frequent bronchiectasis exacerbations may be more likely than those with less frequent exacerbations to experience disease progression based on future exacerbation frequency and lower FEV at baseline, although FEV decline may not differ by baseline exacerbation frequency.
本研究旨在评估基线和随访期间(目标 1)非囊性纤维化支气管扩张症(支气管扩张症)恶化次数的相关性,并确定与恶化频率相关的 FEV 纵向变化(目标 2)。
这是一项回顾性队列研究,纳入了 2008 年 9 月至 2020 年 3 月期间参加美国支气管扩张症和非结核分枝杆菌研究登记处的成年患者。目标 1 的结果是基线(24 个月)与 0 至 24 个月和 24 至 48 个月随访窗口期间恶化之间的相关性。目标 2 的结果是根据基线恶化频率分层,24 个月内 FEV 和 FEV%预计值的变化。
目标 1 队列(N=520)的任何恶化频率基线为 59.2%。总体而言,基线时有≥1 次恶化的患者中,71.4%和 75.0%在 0 至 24 个月和 24 至 48 个月的随访中有≥1 次恶化。基线时发生≥1 次恶化与 0 至 24 个月(P=0.0085)和 24 至 48 个月(P<0.0001)随访期间发生≥1 次恶化显著相关。目标 2 队列(N=431)基线时 FEV 在恶化次数较多的患者中显著降低;然而,从基线到 12 个月(P=0.0002)和 24 个月(P<0.0001),FEV 的下降在有 0、1 和≥2 次恶化的患者之间没有显著差异。在基线时恶化次数较多的患者中,FEV%预测值在基线时(P<0.0001)和 12 个月(P=0.0002)和 24 个月(P<0.0001)时显著降低。
与恶化频率较低的患者相比,频繁发生支气管扩张症恶化的患者可能更有可能根据未来的恶化频率和基线时较低的 FEV 经历疾病进展,尽管 FEV 下降可能与基线时的恶化频率无关。